Burns: An update on current pharmacotherapy

Yesenia Rojas, Celeste Finnerty, Ravi Radhakrishnan, David Herndon

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Introduction: The worldwide occurrence of burn injuries remains high despite efforts to reduce injury incidence through public awareness campaigns and improvements in living conditions. In 2004, almost 11 million people experienced burns severe enough to warrant medical treatment. Advances over the past several decades in aggressive resuscitation, nutrition, excision and grafting have reduced morbidity and mortality. Incorporation of pharmacotherapeutics into treatment regimens may further reduce complications of severe burn injuries. Areas covered: Severe burn injuries, as well as other forms of stress and trauma, trigger a hypermetabolic response that, if left untreated, impedes recovery. In the past two decades, use of anabolic agents, β-adrenergic receptor antagonists and anti-hyperglycemic agents has successfully counteracted post-burn morbidities including catabolism, the catecholamine-mediated response and insulin resistance. Here, the authors review the most up-to-date information on currently used pharmacotherapies in the treatment of these sequelae of severe burns and the insights that have expanded the understanding of the pathophysiology of severe burns. Expert opinion: Existing drugs offer promising advances in the care of burn injuries. Continued gains in the understanding of the molecular mechanisms driving the hypermetabolic response will enable the application of additional existing drugs to be broadened to further attenuate the hypermetabolic response.

Original languageEnglish (US)
Pages (from-to)2485-2494
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number17
DOIs
StatePublished - Dec 2012

Fingerprint

Burns
Drug Therapy
Wounds and Injuries
Morbidity
Anabolic Agents
Adrenergic Antagonists
Social Conditions
Expert Testimony
Resuscitation
Pharmaceutical Preparations
Catecholamines
Insulin Resistance
Therapeutics
Mortality
Incidence

Keywords

  • Burns
  • Growth hormone
  • Hypermetabolic response
  • Ketoconazole
  • Oxandrolone
  • Pharmacotherapy
  • Propranolol

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Burns : An update on current pharmacotherapy. / Rojas, Yesenia; Finnerty, Celeste; Radhakrishnan, Ravi; Herndon, David.

In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 17, 12.2012, p. 2485-2494.

Research output: Contribution to journalArticle

Rojas, Yesenia ; Finnerty, Celeste ; Radhakrishnan, Ravi ; Herndon, David. / Burns : An update on current pharmacotherapy. In: Expert Opinion on Pharmacotherapy. 2012 ; Vol. 13, No. 17. pp. 2485-2494.
@article{d283c37796854df6891745b2e2720e90,
title = "Burns: An update on current pharmacotherapy",
abstract = "Introduction: The worldwide occurrence of burn injuries remains high despite efforts to reduce injury incidence through public awareness campaigns and improvements in living conditions. In 2004, almost 11 million people experienced burns severe enough to warrant medical treatment. Advances over the past several decades in aggressive resuscitation, nutrition, excision and grafting have reduced morbidity and mortality. Incorporation of pharmacotherapeutics into treatment regimens may further reduce complications of severe burn injuries. Areas covered: Severe burn injuries, as well as other forms of stress and trauma, trigger a hypermetabolic response that, if left untreated, impedes recovery. In the past two decades, use of anabolic agents, β-adrenergic receptor antagonists and anti-hyperglycemic agents has successfully counteracted post-burn morbidities including catabolism, the catecholamine-mediated response and insulin resistance. Here, the authors review the most up-to-date information on currently used pharmacotherapies in the treatment of these sequelae of severe burns and the insights that have expanded the understanding of the pathophysiology of severe burns. Expert opinion: Existing drugs offer promising advances in the care of burn injuries. Continued gains in the understanding of the molecular mechanisms driving the hypermetabolic response will enable the application of additional existing drugs to be broadened to further attenuate the hypermetabolic response.",
keywords = "Burns, Growth hormone, Hypermetabolic response, Ketoconazole, Oxandrolone, Pharmacotherapy, Propranolol",
author = "Yesenia Rojas and Celeste Finnerty and Ravi Radhakrishnan and David Herndon",
year = "2012",
month = "12",
doi = "10.1517/14656566.2012.738195",
language = "English (US)",
volume = "13",
pages = "2485--2494",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "17",

}

TY - JOUR

T1 - Burns

T2 - An update on current pharmacotherapy

AU - Rojas, Yesenia

AU - Finnerty, Celeste

AU - Radhakrishnan, Ravi

AU - Herndon, David

PY - 2012/12

Y1 - 2012/12

N2 - Introduction: The worldwide occurrence of burn injuries remains high despite efforts to reduce injury incidence through public awareness campaigns and improvements in living conditions. In 2004, almost 11 million people experienced burns severe enough to warrant medical treatment. Advances over the past several decades in aggressive resuscitation, nutrition, excision and grafting have reduced morbidity and mortality. Incorporation of pharmacotherapeutics into treatment regimens may further reduce complications of severe burn injuries. Areas covered: Severe burn injuries, as well as other forms of stress and trauma, trigger a hypermetabolic response that, if left untreated, impedes recovery. In the past two decades, use of anabolic agents, β-adrenergic receptor antagonists and anti-hyperglycemic agents has successfully counteracted post-burn morbidities including catabolism, the catecholamine-mediated response and insulin resistance. Here, the authors review the most up-to-date information on currently used pharmacotherapies in the treatment of these sequelae of severe burns and the insights that have expanded the understanding of the pathophysiology of severe burns. Expert opinion: Existing drugs offer promising advances in the care of burn injuries. Continued gains in the understanding of the molecular mechanisms driving the hypermetabolic response will enable the application of additional existing drugs to be broadened to further attenuate the hypermetabolic response.

AB - Introduction: The worldwide occurrence of burn injuries remains high despite efforts to reduce injury incidence through public awareness campaigns and improvements in living conditions. In 2004, almost 11 million people experienced burns severe enough to warrant medical treatment. Advances over the past several decades in aggressive resuscitation, nutrition, excision and grafting have reduced morbidity and mortality. Incorporation of pharmacotherapeutics into treatment regimens may further reduce complications of severe burn injuries. Areas covered: Severe burn injuries, as well as other forms of stress and trauma, trigger a hypermetabolic response that, if left untreated, impedes recovery. In the past two decades, use of anabolic agents, β-adrenergic receptor antagonists and anti-hyperglycemic agents has successfully counteracted post-burn morbidities including catabolism, the catecholamine-mediated response and insulin resistance. Here, the authors review the most up-to-date information on currently used pharmacotherapies in the treatment of these sequelae of severe burns and the insights that have expanded the understanding of the pathophysiology of severe burns. Expert opinion: Existing drugs offer promising advances in the care of burn injuries. Continued gains in the understanding of the molecular mechanisms driving the hypermetabolic response will enable the application of additional existing drugs to be broadened to further attenuate the hypermetabolic response.

KW - Burns

KW - Growth hormone

KW - Hypermetabolic response

KW - Ketoconazole

KW - Oxandrolone

KW - Pharmacotherapy

KW - Propranolol

UR - http://www.scopus.com/inward/record.url?scp=84869773994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869773994&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.738195

DO - 10.1517/14656566.2012.738195

M3 - Article

C2 - 23121414

AN - SCOPUS:84869773994

VL - 13

SP - 2485

EP - 2494

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 17

ER -